Genentech settles on Cabilly
Executive Summary
Genentech resolves its long-standing dispute with MedImmune over its Cabilly patent, which relates to the process for producing antibodies, the biotech announces. MedImmune, which licenses the patent along with Johnson & Johnson, ImClone and Abbott, filed suit in 2003 challenging the patent, but it was not until a decision by the U.S. Supreme Court in January that the firm gained the necessary legal standing (1"The Pink Sheet," Jan. 15, 2007, p. 7). Under the settlement, the manufacturer of Synagis (palivizumab) can obtain licenses for certain additional pipeline products under the Cabilly patent family, including motavizumab. Financial terms of the settlement were not disclosed
You may also be interested in...
Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
Declaratory Judgments For Generic Firms May Be Easier After MedImmune Case
The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could be in a case brought by Teva against Novartis regarding Famvir
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.